Literature DB >> 23793581

Caveolin-1 deficiency protects against mesangial matrix expansion in a mouse model of type 1 diabetic nephropathy.

T H Guan1, G Chen, B Gao, M R Janssen, L Uttarwar, A J Ingram, J C Krepinsky.   

Abstract

AIMS/HYPOTHESIS: Glomerular matrix protein accumulation, mediated largely by resident mesangial cells (MCs), is central to the pathogenesis of diabetic nephropathy. We previously showed that caveolin (CAV)-1/caveolae mediate matrix upregulation by MCs in response to high glucose and TGFβ, two important pathogenic mediators of diabetic glomerular sclerosis. Here, we evaluated the in vivo role of CAV-1/caveolae in the development of diabetic nephropathy.
METHODS: Diabetes was induced in Cav1-knockout (KO) mice and their wild-type (WT) counterparts by streptozotocin injection. After 10 months, kidneys were evaluated for the development of nephropathy, including glomerular sclerosis and upregulation of matrix proteins. Parallel experiments assessing glucose-induced matrix upregulation were carried out in MCs isolated from KO mice.
RESULTS: KO diabetic mice developed hyperglycaemia and renal hypertrophy, but were protected from developing albuminuria and glomerular sclerosis compared with WT mice. KO mice were significantly protected from the upregulation of glomerular collagen I, fibronectin, connective tissue growth factor (CTGF) and TGFβ. In vitro, glucose induced collagen I A1 promoter activation and collagen I, fibronectin and CTGF protein upregulation in WT but not KO MCs. Re-expression of Cav1 in KO cells restored this response. CONCLUSIONS/
INTERPRETATION: Cav1 deletion rendered significant protection from glomerular matrix accumulation and albuminuria in a mouse model of type 1 diabetes. These studies provide a foundation for the development of renal-targeted interference with CAV-1/caveolae as a novel approach to the treatment of diabetic nephropathy.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23793581     DOI: 10.1007/s00125-013-2968-z

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  50 in total

Review 1.  The multiple faces of caveolae.

Authors:  Robert G Parton; Kai Simons
Journal:  Nat Rev Mol Cell Biol       Date:  2007-03       Impact factor: 94.444

2.  Unaltered size selectivity of the glomerular filtration barrier in caveolin-1 knockout mice.

Authors:  Gustaf Grände; Catarina Rippe; Anna Rippe; Awahan Rahman; Karl Swärd; Bengt Rippe
Journal:  Am J Physiol Renal Physiol       Date:  2009-05-27

3.  The significance of caveolae in the glomeruli in glomerular disease.

Authors:  Takahito Moriyama; Yuki Tsuruta; Ari Shimizu; Mitsuyo Itabashi; Takashi Takei; Shigeru Horita; Keiko Uchida; Kosaku Nitta
Journal:  J Clin Pathol       Date:  2011-03-30       Impact factor: 3.411

4.  eNOS and caveolin-1 gene polymorphisms interaction and intima media thickness: a proof of concept study in ESRD patients.

Authors:  Alessandra Testa; Belinda Spoto; Maria Cristina Sanguedolce; Rosa M Parlongo; Anna Pisano; Giovanni Tripepi; Francesco A Benedetto; Francesca Mallamaci; Carmine Zoccali
Journal:  Am J Hypertens       Date:  2011-10-06       Impact factor: 2.689

5.  Fibronectin matrix turnover occurs through a caveolin-1-dependent process.

Authors:  Jane Sottile; Jennifer Chandler
Journal:  Mol Biol Cell       Date:  2004-11-24       Impact factor: 4.138

6.  Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC beta inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes.

Authors:  D Koya; M Haneda; H Nakagawa; K Isshiki; H Sato; S Maeda; T Sugimoto; H Yasuda; A Kashiwagi; D K Ways; G L King; R Kikkawa
Journal:  FASEB J       Date:  2000-03       Impact factor: 5.191

Review 7.  Diabetic nephropathy: where hemodynamics meets metabolism.

Authors:  J M Forbes; K Fukami; M E Cooper
Journal:  Exp Clin Endocrinol Diabetes       Date:  2007-02       Impact factor: 2.949

8.  Antifibrotic properties of caveolin-1 scaffolding domain in vitro and in vivo.

Authors:  Elena Tourkina; Mathieu Richard; Pal Gööz; Michael Bonner; Jaspreet Pannu; Russell Harley; Pascal N Bernatchez; William C Sessa; Richard M Silver; Stanley Hoffman
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2008-01-18       Impact factor: 5.464

9.  Caveolin-1 phosphorylation is required for stretch-induced EGFR and Akt activation in mesangial cells.

Authors:  Baifang Zhang; Fangfang Peng; Dongcheng Wu; Alistair J Ingram; Bo Gao; Joan C Krepinsky
Journal:  Cell Signal       Date:  2007-03-19       Impact factor: 4.315

10.  Targeting of RhoA/ROCK signaling ameliorates progression of diabetic nephropathy independent of glucose control.

Authors:  Vasantha Kolavennu; Lixia Zeng; Hui Peng; Yin Wang; Farhad R Danesh
Journal:  Diabetes       Date:  2007-12-14       Impact factor: 9.461

View more
  11 in total

1.  Pigment epithelium-derived factor inhibits caveolin-induced interleukin-8 gene expression and proliferation of human prostate cancer cells.

Authors:  Takanori Matsui; Ayako Ojima; Yuichiro Higashimoto; Junichi Taira; Kei Fukami; Sho-Ichi Yamagishi
Journal:  Oncol Lett       Date:  2015-08-04       Impact factor: 2.967

2.  Interaction among Caveolin-1 genotypes (rs3807987/rs7804372), H. pylori infection, and risk of gastric cancer in a Chinese population.

Authors:  Ye Zhang; Xue-jun Hu; Lu-lu Zhang; Li-ping Sun; Yuan Yuan; Xiu-juan Qu; Yun-peng Liu
Journal:  Tumour Biol       Date:  2013-09-25

3.  Loss of Epithelial Membrane Protein 2 Aggravates Podocyte Injury via Upregulation of Caveolin-1.

Authors:  Xiaoyang Wan; Zhaohong Chen; Won-Il Choi; Heon Yung Gee; Friedhelm Hildebrandt; Weibin Zhou
Journal:  J Am Soc Nephrol       Date:  2015-08-11       Impact factor: 10.121

4.  High glucose induces formation of tau hyperphosphorylation via Cav-1-mTOR pathway: A potential molecular mechanism for diabetes-induced cognitive dysfunction.

Authors:  Jing Wu; Shan-Lei Zhou; Lin-Hua Pi; Xia-Jie Shi; Ling-Ran Ma; Zi Chen; Min-Li Qu; Xin Li; Sheng-Dan Nie; Duan-Fang Liao; Jin-Jing Pei; Shan Wang
Journal:  Oncotarget       Date:  2017-06-20

5.  Caveolin-1 regulation of Sp1 controls production of the antifibrotic protein follistatin in kidney mesangial cells.

Authors:  Neel Mehta; Dan Zhang; Renzhong Li; Tony Wang; Agata Gava; Pavithra Parthasarathy; Bo Gao; Joan C Krepinsky
Journal:  Cell Commun Signal       Date:  2019-04-17       Impact factor: 5.712

6.  miR299a-5p promotes renal fibrosis by suppressing the antifibrotic actions of follistatin.

Authors:  Neel Mehta; Renzhong Li; Dan Zhang; Asfia Soomro; Juehua He; Ivan Zhang; Melissa MacDonald; Bo Gao; Joan C Krepinsky
Journal:  Sci Rep       Date:  2021-01-08       Impact factor: 4.379

7.  Injury-induced Cavl-expressing cells at lesion rostral side play major roles in spinal cord regeneration.

Authors:  Chih-Wei Zeng; Yasuhiro Kamei; Shuji Shigenobu; Jin-Chuan Sheu; Huai-Jen Tsai
Journal:  Open Biol       Date:  2021-02-24       Impact factor: 6.411

Review 8.  MRTF: Basic Biology and Role in Kidney Disease.

Authors:  Maria Zena Miranda; Zsuzsanna Lichner; Katalin Szászi; András Kapus
Journal:  Int J Mol Sci       Date:  2021-06-03       Impact factor: 5.923

Review 9.  Role of Caveolin-1 in Diabetes and Its Complications.

Authors:  Dania Haddad; Ashraf Al Madhoun; Rasheeba Nizam; Fahd Al-Mulla
Journal:  Oxid Med Cell Longev       Date:  2020-01-27       Impact factor: 6.543

Review 10.  Caveolin-1 Regulates Cellular Metabolism: A Potential Therapeutic Target in Kidney Disease.

Authors:  Shilu Luo; Ming Yang; Hao Zhao; Yachun Han; Na Jiang; Jinfei Yang; Wei Chen; Chenrui Li; Yan Liu; Chanyue Zhao; Lin Sun
Journal:  Front Pharmacol       Date:  2021-12-10       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.